Hemogenyx Pharmaceuticals annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Depreciation & Amortization Growth & History (HEMO)
Hemogenyx Pharmaceuticals's depreciation and amortization was £588,753 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £588,753 | −£50,532 | −7.90% |
| 2024 | 2024-12-31 | £639,285 | −£6,396 | −0.99% |
| 2023 | 2023-12-31 | £645,681 | £81,609 | +14.47% |
| 2022 | 2022-12-31 | £564,072 | £437,732 | +346.47% |
| 2021 | 2021-12-31 | £126,340 | £19,587 | +18.35% |
| 2020 | 2020-12-31 | £106,753 | — | — |
Hemogenyx Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's depreciation and amortization increased from £106,753 to £588,753, a change of £482,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗